PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2007 September; 8(3): E203–E208.
Published online 2007 September 21. doi:  10.1208/pt0803077
PMCID: PMC2750573

Mucoadhesive bilayer tablets of propranolol hydrochloride

Abstract

The purpose of this research was to study mucoadhesive bilayer buccal tablets of propranolol hydrochloride using the bioadhesive polymers sodium alginate (Na-alginate) and Carbopol 934P (CP) along with ethyl cellulose as an impermeable backing layer. The tablets were evaluated for weight variation, thickness, hardness, friability, surface pH, mucoadhesive strength, swelling index, in vitro drug release, ex vivo drug permeation, ex vivo mucoadhesion, and in vivo pharmacodynamics in rabbits. Tablets containing Na-alginate and CP in the ratio of 5[ratio]1 (F2) had the maximum percentage of in vitro drug release without disinte-gration in 12 hours. The swelling index was proportional to Na-alginate content and inversely proportional to CP content. The surface pH of all tablets was found to be satis-factory (7.0±1.5), close to neutral pH; hence, buccal cavity irritation should not occur with these tablets. The mechanism of drug release was found to be non-Fickian diffusion and followed zero-order kinetics. The formulation F4 was optimized based on good biodhesive strength (28.9±0.99 g) and sustained in vitro drug permeation (68.65%±3.69% for 12 hours). The behavior of formulation F4 was examined in human saliva, and both the drug and the buccal tablet were found to be stable. The formulation F4 was applied to rabbit oral mucosa for in vivo studies. The formulation inhibited isoprenaline-induced tachycardia. The studies conducted in rabbits confirmed the sustained release as compared with intravenous administration.

Keywords: Mucoadhesion, bilayer device, buccal drug delivery, propranolol hydrochloride, sodium alginate, Carbopol 934

Full Text

The Full Text of this article is available as a PDF (202K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Gavini E, Sanna V, Juliano C, Bonferoni MC, Giunchedi P. Mucoadhesive vaginal tablets as veterinary delivery system for the controlled release of an antimicrobial drug. Acriflavine.AAPS PharmSciTech. 2002;3:Article 20. [serial online]. [PMC free article] [PubMed]
2. Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci. 1992;81:1–10. doi: 10.1002/jps.2600810102. [PubMed] [Cross Ref]
3. Ali J, Khar RK, Ahuja A. Formulation and characterization of a buccoadhesive erodible tablet for the treatment of oral lesions. Pharmazie. 1998;53:329–334. [PubMed]
4. Kohda Y, Kobayashi H, Baba Y, et al. Controlled release of lidocaine hydrochloride from buccal mucosa-adhesive films with solid dispersion. Int J Pharm. 1983;15:147–155.
5. Nair MK, Chien YW. Development of anticandidal delivery systems. II. mucoadhesive devices for prolonged drug delivery in the oral cavity. Drug Dev Ind Pharm. 2007;22:243–253. doi: 10.3109/03639049609058568. [Cross Ref]
6. Parodi B, Russo E, Caviglioli G, Cafaggi S, Bignardi G. Development and characterization of a buccoadhesive dosage form of oxycodone hydrochloride. Drug Dev Ind Pharm. 2007;22:445–450. doi: 10.3109/03639049609069353. [Cross Ref]
7. Shin SC, Bum JP, Choi JS. Enhanced bioavailability by buccal administration of triamcinolone acetonide from the bioadhesive gels in rabbits. Int J Pharm. 2000;209:37–43. doi: 10.1016/S0378-5173(00)00542-1. [PubMed] [Cross Ref]
8. Nagai T, Konishi R. Buccal/gingival drug delivery systems. J Control Release. 1987;6:353–360. doi: 10.1016/0168-3659(87)90088-5. [Cross Ref]
9. Cid E, Mella F, Lucchini L., Carcamo M, Monasterio J. Plasma concentrations and biovailability of propranolol by oral, rectal and intravenous administration in man. Biopharm Drug Dispos. 1986;7:559–566. doi: 10.1002/bdd.2510070605. [PubMed] [Cross Ref]
10. Walle T, Conradi EC, Walle UK, Fagan TC, Gaffney TE. The predictable relationship between plasma levels and dose during chronic propranolol therapy. Clin Pharmacol Ther. 1978;24:668–677. [PubMed]
11. Kemken J, Ziegler A, Muller BW. Pharmacodynamic effects of transdermal bupranolol and timolol in vivo: comparison of micro emulsions and matrix patches as vehicle. Methods Find Exp Clin Pharmacol. 1991;13:361–365. [PubMed]
12. Gupta A, Garg S, Khar RK. Measurement of bioadhesive strength of muco-adhesive buccal tablets: design of an in-vitro assembly. Indian Drug. 1992;30:152–155.
13. Bottenberg P, Cleymaet R, Muynek CD, Remon JP, Coomans D, Slop D. Development and testing of bioadhesive, flurode-containing slow-release tablets for oral use. J Pharm Pharmacol. 1991;43:457–464. [PubMed]
14. Kemken J, Ziegler A, Muller BW. Investigation into the pharmacodynamic effects of dermally administered microemulsions containing beta-blockers. J Pharm Pharmacol. 1991;43:679–684. [PubMed]
15. De Vries ME, Bodde HE, Verhoef JC, Junginger HE. Developments in buccal drug delivery. Crit Rev Ther Drug Carrier Syst. 1991;8:271–303. [PubMed]
16. Chidambaram N, Srivatsava AK. Buccal drug delivery systems. Drug Dev Ind Pharm. 1995;21:1009–1036. doi: 10.3109/03639049509069802. [Cross Ref]
17. Duchene D, Touchard F, Pappas NA. Pharmaceutical and medical aspects of bioadhesive systems for drug administration. Drug Dev Ind Pharm. 1988;14:283–318. doi: 10.3109/03639048809151972. [Cross Ref]
18. Guo JH, Cooklock M. The effect of backing materials and multilayered systems on the characteristics of bioadhesive buccal patches. J Pharm Pharmacol. 2007;48:255–257. [PubMed]
19. Peppas NA, Bury PA. Surface interfacial and molecular aspects of polymer bioadhesion on soft tissues. J Control Release. 1985;2:257–275. doi: 10.1016/0168-3659(85)90050-1. [Cross Ref]
20. Ilango R, Kavimani S, Mullaicharam AR, Jayakar B. In vitro studies on buccal strips of glibenclamide using chitosan. Indian J Pharm Sci. 1997;59:232–235.
21. Agarwal V, Mishra B. Design, development, and biopharmaceutical properties of buccoadhesive compacts of omeprazole. Drug Dev Ind Pharm. 1999;25:701–709. doi: 10.1081/DDC-100102229. [PubMed] [Cross Ref]
22. Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 1985;60:110–111. [PubMed]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists